For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. "Vector" refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
Scope of the Report:
The worldwide market for Recombinant Vector Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Recombinant Vector Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- SANOFI PASTEUR S.A.
- Novartis
- GSK
- CNBG
- ChengDa Bio
- Changsheng Life
- Zhifei
- SINOVAC BIOTECH
- NuoCheng Bio
- Hualan Bio
- Kangtai
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Varicella
- Influenza
- Polio
- Hepatitis A
- Rabies
- BCG
- Hepatitis B
- Pertussis, Diphtheria, tetanus
- Pneumococcal
- Others
Market Segment by Applications, can be divided into
- For Adult
- For Child
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Vector Vaccines product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Vector Vaccines, with price, sales, revenue and global market share of Recombinant Vector Vaccines in 2017 and 2018.
Chapter 3, the Recombinant Vector Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Vector Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Recombinant Vector Vaccines market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Recombinant Vector Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.